AtriCure to Announce Second Quarter 2024 Financial Results

Rhea-AI Summary

AtriCure (Nasdaq: ATRC) will announce its second quarter 2024 financial results on July 30, 2024. The company specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. A webcast will be hosted at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested individuals can register online, and both live and replay versions of the webcast will be accessible at AtriCure's investor relations site.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024.

AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, July 30, 2024, to discuss its second quarter 2024 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709821917/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Marissa Bych

Gilmartin Group

Investor Relations

marissa@gilmartinir.com

Source: AtriCure, Inc.

FAQ

When will AtriCure announce its Q2 2024 financial results?

AtriCure will announce its second quarter 2024 financial results on July 30, 2024.

What time is the AtriCure Q2 2024 financial results webcast?

The AtriCure Q2 2024 financial results webcast will be held at 4:30 p.m. Eastern Time on July 30, 2024.

How can I register for the AtriCure Q2 2024 financial results webcast?

You can register for the AtriCure Q2 2024 financial results webcast online via the provided link in the press release.

Where can I access the live and replay versions of AtriCure's Q2 2024 financial results webcast?

The live and replay versions of AtriCure's Q2 2024 financial results webcast will be available at AtriCure's investor relations site.